MARKET

BSTC

BSTC

Biospecifics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

58.99
-3.21
-5.16%
Closed 16:11 06/01 EDT
OPEN
61.09
PREV CLOSE
62.20
HIGH
62.22
LOW
58.99
VOLUME
35.50K
TURNOVER
--
52 WEEK HIGH
66.51
52 WEEK LOW
42.00
MARKET CAP
432.61M
P/E (TTM)
17.68
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BSTC stock price target is 90.00 with a high estimate of 90.00 and a low estimate of 90.00.

EPS

BSTC News

More
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28)
Benzinga · 4d ago
One Analyst Thinks BioSpecifics Technologies Corp.'s (NASDAQ:BSTC) Revenues Are Under Threat
Simply Wall St. · 05/16 13:30
BioSpecifics Names Joseph Truitt Permanent CEO
Benzinga · 05/11 12:17
BioSpecifics Technologies Q1 EPS $0.610 Up From $0.600 YoY, Sales $9.669M Up From $8.129M YoY
BioSpecifics Technologies (NASDAQ:BSTC) reported quarterly earnings of $0.610 per share. This is a 1.67 percent increase over earnings of $0.600 per share from the same period last year. The company reported $9.669
Benzinga · 05/11 12:12
BioSpecifics Reports First Quarter 2020 Financial and Operating Results
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced its financia
PR Newswire · 05/11 12:05
BioSpecifics Names Joseph Truitt as Permanent Chief Executive Officer
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced the appointm
PR Newswire · 05/11 12:00
Zacks.com featured highlights include: BioSpecificsTechnologies, eXp World, Elbit Systems and KoninklijkeVopak
Zacks.com featured highlights include: BioSpecificsTechnologies, eXp World, Elbit Systems and KoninklijkeVopak
Zacks · 05/07 13:49
These 3 Biotech Stocks Are Outperforming Their Peers Here's Why
Investor's Business Daily · 05/05 13:00

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About BSTC

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren's contracture and Peyronie's disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.
More

Webull offers kinds of BioSpecifics Technologies Corp. stock information, including NASDAQ:BSTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BSTC stock news, and many more online research tools to help you make informed decisions.